Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Oramed Pharmaceuticals	NuCana	Oncternal Therapeutics	Larimar Therapeutics	Galera Therapeutics
Symbol	NASDAQ:ORMP	NASDAQ:NCNA	NASDAQ:ONCT	NASDAQ:LRMR	NASDAQ:GRTX
Price Information
Current Price	$9.28	$4.42	$6.26	$12.84	$7.52
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.3	1.5	1.7	1.6	1.6
Analysis Score	3.5	3.4	4.5	3.5	3.5
Community Score	3.1	2.6	3.4	2.1	2.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	1.7	1.7
Earnings & Valuation Score	0.0	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$13.33	$17.50	$15.20	$29.00	$17.00
% Upside from Price Target	43.68% upside	295.93% upside	142.81% upside	125.86% upside	126.06% upside
Trade Information
Market Cap	$272.55 million	$214.35 million	$309.02 million	$197.33 million	$187.82 million
Beta	1.98	0.92	1.66	0.65	1.89
Average Volume	790,876	516,923	1,731,715	68,954	67,944
Sales & Book Value
Annual Revenue	$2.71 million	N/A	$2.42 million	N/A	N/A
Price / Sales	100.57	N/A	127.69	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.40 per share	$2.52 per share	$0.93 per share	$17.22 per share	$2.81 per share
Price / Book	6.63	N/A	6.73	N/A	N/A
Profitability
Net Income	$-11,510,000.00	$-27,340,000.00	$-34,190,000.00	$-45,410,000.00	$-51,930,000.00
EPS	($0.56)	($0.84)	($1.56)	N/A	($16.31)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-424.76%	N/A	-746.10%	N/A	N/A
Return on Equity (ROE)	-45.93%	-35.90%	-150.58%	-38.70%	-151.01%
Return on Assets (ROA)	-30.33%	-32.56%	-91.87%	-31.40%	-60.72%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	8.93%	12.48%	3.01%	20.82%	8.79%
Quick Ratio	8.93%	12.48%	3.01%	20.82%	8.79%
Ownership Information
Institutional Ownership Percentage	6.03%	84.13%	10.79%	88.76%	75.41%
Insider Ownership Percentage	16.10%	N/A	10.90%	5.10%	19.30%
Miscellaneous
Employees	N/A	27	12	28	32
Shares Outstanding	29.37 million	48.50 million	49.36 million	15.37 million	24.98 million
Next Earnings Date	7/6/2021 (Estimated)	5/18/2021 (Estimated)	5/6/2021 (Estimated)	5/6/2021 (Estimated)	5/11/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ... apnews.com - March 12 at 5:40 PM
	Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments finance.yahoo.com - March 11 at 7:25 AM
	Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference finance.yahoo.com - March 10 at 8:15 AM
	We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully finance.yahoo.com - February 19 at 11:40 AM
	Is GRTX A Good Stock To Buy Now? finance.yahoo.com - December 7 at 8:45 PM
	Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates finance.yahoo.com - November 10 at 10:09 AM
	Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference finance.yahoo.com - November 3 at 12:54 PM
	AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma seekingalpha.com - October 30 at 7:36 AM
	Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination ... apnews.com - October 29 at 12:10 AM
	Galera down 6% on disappointing data on lead drug in pancreatic cancer seekingalpha.com - October 27 at 11:45 PM
	Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer finance.yahoo.com - October 27 at 6:45 PM
	Lianluo Smart, Galera Therapeutics leads healthcare gainers; BioSig Technologies, Aileron Therapeutics among major losers seekingalpha.com - October 26 at 11:33 AM
	Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer finance.yahoo.com - October 23 at 8:46 PM
	Galera Therapeutics Inc. barrons.com - October 23 at 3:42 PM
	Dosing underway for Galera Therapeutics' GC4711 in early-stage lung cancer study seekingalpha.com - October 22 at 2:17 PM
	Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer finance.yahoo.com - October 22 at 9:13 AM
	How Many Galera Therapeutics, Inc. (NASDAQ:GRTX) Shares Do Institutions Own? finance.yahoo.com - October 20 at 11:09 AM
	Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer benzinga.com - September 22 at 8:32 AM
	Dosing is underway for Galera's lead asset in mid-stage COVID-19 study seekingalpha.com - September 16 at 1:29 PM
	Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 finance.yahoo.com - September 16 at 8:28 AM
	Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit finance.yahoo.com - September 14 at 9:08 AM
	Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer finance.yahoo.com - September 8 at 8:13 AM
	Galera Therapeutics: Reasonable Valuation With Fast Track And Breakthrough Designation seekingalpha.com - September 7 at 11:16 AM
	Galera Therapeutics, Inc. Common Stock (GRTX) nasdaq.com - August 14 at 12:00 PM
	Galera Therapeutics EPS beats by $0.01 seekingalpha.com - August 10 at 11:06 AM

Date	Company	Brokerage	Action
2/15/2021	Oramed Pharmaceuticals	Aegis	Reiterated Rating
2/9/2021	Oramed Pharmaceuticals	National Securities	Initiated Coverage
12/3/2020	Oramed Pharmaceuticals	Alliance Global Partners	Initiated Coverage
7/13/2020	Oramed Pharmaceuticals	HC Wainwright	Reiterated Rating
9/11/2019	Oramed Pharmaceuticals	LADENBURG THALM/SH SH	Initiated Coverage
7/16/2018	Oramed Pharmaceuticals	B. Riley	Downgrade
3/30/2021	NuCana	William Blair	Reiterated Rating
10/22/2020	NuCana	Truist	Initiated Coverage
9/21/2020	NuCana	Oppenheimer	Reiterated Rating
8/21/2020	NuCana	Piper Sandler	Boost Price Target
7/29/2020	NuCana	Cowen	Reiterated Rating
11/15/2019	NuCana	Piper Jaffray Companies	Lower Price Target
8/21/2019	NuCana	Citigroup	Set Price Target
3/30/2021	Oncternal Therapeutics	Brookline Capital Management	Reiterated Rating
3/30/2021	Oncternal Therapeutics	Brookline Capital Acquisition	Initiated Coverage
2/23/2021	Oncternal Therapeutics	Northland Securities	Initiated Coverage
2/10/2021	Larimar Therapeutics	JMP Securities	Initiated Coverage
12/16/2020	Galera Therapeutics	Credit Suisse Group	Upgrade
10/28/2020	Galera Therapeutics	Smith Barney Citigroup	Boost Price Target
12/2/2019	Galera Therapeutics	BTIG Research	Initiated Coverage
12/2/2019	Galera Therapeutics	Bank of America	Initiated Coverage

(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources